Turn Therapeutics (TTRX)

• Market cap: $408M
• 1 day: 5.99%
• 5 days: 34.63%
• 1 month: 40.54%
• 3 months: 109.5%
• 6 months: 268.49%
• Year to date: 186.78%
• 1 year: 92.14%
• 5 years: 92.14%
• 10 years: 92.14%
• Sector: Healthcare
• Industry: Biotechnology

About: Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Employees: 2